TAVR Retrievable Delivery System Landscape 2026
TAVR Retrievable Delivery System Landscape 2026
Retrievable and repositionable delivery systems have become a critical engineering differentiator in TAVR, directly targeting paravalvular leak, malpositioning, and permanent pacemaker risk. This dataset spans patent filings and clinical literature from 2012 through 2025.
Retrievability as the Central Engineering Problem in TAVR
Transcatheter aortic valve replacement has evolved from an experimental procedure for inoperable patients into the dominant treatment for aortic stenosis across all surgical risk categories. Within this maturing field, retrievable and repositionable delivery systems address the persistent clinical problems of malpositioning, paravalvular leak, and permanent pacemaker requirement.
Three interrelated engineering domains define TAVR retrievable delivery system technology in this dataset: mechanical recapture and resheathing mechanisms allowing partial or full withdrawal before final release; split-type two-stage anchoring architectures that separate stent anchoring from valve deployment; and self-expanding frame geometries engineered to permit controlled recapture without structural compromise to bioprosthetic leaflets.
First-generation devices — Edwards SAPIEN and Medtronic CoreValve — lacked repositionability, with paravalvular leak rates of 12–23% representing the principal unsolved problem. The Medtronic Evolut R introduced recapture functionality, with recapture maneuvers used in 12.5% of 320 consecutive clinical cases, demonstrating routine real-world reliance on repositioning capability.
In this dataset, two named assignees account for all 7 patent records retrieved. Beijing Balance Medical Technology Co., Ltd. leads by filing volume in retrieved records with 6 filings across 5 jurisdictions, while Medtronic Vascular, Inc. accounts for 1 US filing. The most recent filings (2023–2025) represent an emerging split-type two-stage anchoring paradigm approaching commercialization.
Filing Activity and Clinical Evidence by Technology Cluster
The dataset spans four distinguishable technology clusters, ranging from the clinically mature Evolut mechanical resheathing platform to the emerging split-type anchoring architecture. Patent and clinical record counts differ by cluster, reflecting the distinct maturation stages of each approach.
Patent Records by Technology Cluster — TAVR Retrievable Delivery Systems (Dataset Snapshot)
In this dataset, the split-type anchoring architecture accounts for 6 of 7 patent records, concentrated in filings by Beijing Balance Medical Technology Co., Ltd. across 2023–2025, while the delivery system stabilization cluster holds 1 record from Medtronic Vascular.
↗ Click bars to exploreClinical Literature Records by Publication Year — TAVR Retrievable Delivery Systems (Dataset Snapshot)
In this dataset, clinical literature records peak in the 2017–2020 period, reflecting the comparative evaluation era for second-generation retrievable systems including the Evolut R and Lotus platforms.
↗ Click bars to exploreKey Indications Where TAVR Retrievable Delivery Systems Are Applied
Retrievable TAVR delivery systems are deployed across five distinct clinical contexts, each placing different demands on recapture precision, anchoring reliability, and anatomical adaptability — from high-risk inoperable patients to emerging valve-in-TAVR redo procedures.
High-Risk and Inoperable Patients
The founding indication for retrievable delivery system development. The 2019 single-center Lotus evaluation enrolled patients with a mean STS score of 6.5% and mean EuroScore I of 25.3%, representing the high-risk population for whom full retrievability reduces procedural risk in patients who cannot tolerate emergent conversion to open surgery. Zero valve embolization events were recorded in the first 100 consecutive Lotus implantations.
Surgical High-RiskIntermediate- and Low-Risk Expansion
Retrieved reviews including the 2022 indications update document expansion of TAVR toward lower-risk and younger patients. For this population, retrievability and precise positioning are more critical because lifetime valve management and future coronary access must be considered at the time of index implantation. The 2018 indications review also confirms this shift toward uncharted lower-risk indications.
Low-Risk ExpansionPure Native Aortic Regurgitation
The absence of calcification makes conventional anchoring unreliable in non-calcific aortic regurgitation. The 2016 India case report explicitly states that recapturable and repositionable CoreValve Evolut R technology enabled TAVR in native AR. The 2022 outcomes review of newer- vs. early-generation devices in pure native AR and Beijing Balance Medical’s split-type anchoring stent — which integrates with leaflet and subvalvular tissue independent of calcification — directly address this anatomical challenge.
Non-Calcific ARValve-in-TAVR Redo Procedures
As prior TAVR recipients age and their transcatheter valves degenerate, valve-in-TAVR is emerging as a dedicated indication. The 2020 three-center valve-in-valve comparison study analyzed hemodynamic and 1-year outcomes in degenerated transcatheter versus surgical bioprostheses, confirming that precise coaxial positioning within an existing stent frame demands delivery system precision beyond what original platforms were designed to address. The 2022 indications update signals growing engineering demand for repositionable systems in redo procedures.
Redo TAVRKey Patent Assignees in TAVR Retrievable Delivery Systems (Retrieved Records)
In this dataset, 2 named assignees account for all 7 patent records retrieved. Beijing Balance Medical Technology Co., Ltd. holds 6 filings in retrieved records across 5 jurisdictions (2023–2025), while Medtronic Vascular, Inc. holds 1 US filing (2018) on delivery system stabilization.
Patent Filings by Assignee — TAVR Retrievable Delivery Systems (Dataset Snapshot)
↗ Click bars to exploreBeijing Balance Medical Technology Co., Ltd.
Beijing Balance Medical holds 6 patent filings in this dataset spanning 5 jurisdictions: Canada (2023, pending), Singapore (2024, pending), European Patent Office (2024, active), India (2024, pending), and the United States (2025, two active granted patents). All six filings protect variants of a split-type precisely-anchorable aortic valve architecture, in which a patient-image-matched anchoring stent is deployed first and then acts as a landing zone for a second-stage transcatheter biological valve. The concentrated multi-jurisdictional 2023–2025 filing pattern across all major medical device markets is consistent with a late-stage pre-commercialization IP strategy.
ChinaMedtronic Vascular, Inc.
Medtronic Vascular holds 1 patent record in this dataset — a US patent filed in 2018 (now inactive) covering a stabilization and advancement system for direct aortic transcatheter aortic valve implantation. The patent addresses catheter angulation challenges specific to the transaortic access route. While this single record understates Medtronic’s broader portfolio, it confirms US jurisdiction as a key engineering battleground and documents Medtronic’s delivery system ergonomics focus alongside the Evolut platform’s clinical recapture capability (used in 12.5% of 320 consecutive cases per 2018 clinical data).
United StatesFour Forward-Looking Engineering Directions in TAVR Delivery Systems
The most recent patent filings (2023–2025) and clinical literature (2021–2022) in this dataset point to four forward-looking engineering directions that extend beyond current recapture and resheathing paradigms.
Image-Guided Patient-Specific Anchoring
The Beijing Balance Medical split-type system explicitly incorporates 3D reconstruction of patient imaging data to shape-match the anchoring stent to individual native anatomy. This represents a shift from size-standardized devices toward patient-customized delivery geometry. The US-granted patent (2025) and EP-active counterpart (2024) are the primary evidence signals for this direction in the dataset.
Non-Calcific Aortic Regurgitation as Standalone Indication
Multiple 2021–2022 records address TAVR for pure native aortic regurgitation using newer-generation devices. The 2022 outcomes study comparing newer- vs. early-generation devices in pure native AR documents clinical progress. The split-type anchoring approach — integrating with leaflet and subvalvular tissue rather than relying on calcific landing zones — is architected specifically for this indication, suggesting a dedicated commercial pathway.
Mechanical Resheathing (Evolut) vs. Full Retrievability (Lotus): Key Dimensions
Click any row to explore further.
| Dimension | Evolut R / PRO (Medtronic) | Lotus Valve (Boston Scientific) |
|---|---|---|
| Expansion Mechanism | Self-expanding nitinol frame | Mechanically expanded nitinol braid via rotating delivery handle |
| Retrievability Extent | Partial recapture and resheathing before final release | Full retrieval even after near-complete deployment |
| Rapid Pacing Requirement | Required for balloon post-dilation; not for initial deployment | Controlled deployment independent of rapid pacing |
| Real-World Recapture Rate | 12.5% of 320 consecutive cases (2018 prospective single-center study) | Zero valve embolization in first 100 consecutive implantations (2019) |
| Paravalvular Leak | PRO outer pericardial skirt added to address PVL vs. Evolut R | Lower PVL vs. Sapien 3 in 11-study meta-analysis of 2,836 patients (2020) |
| PVL Reduction Mechanism | Outer pericardial skirt (PRO); frame geometry optimization | Adaptive sealing enabled by controlled mechanical expansion |
| Key Comparative Studies”> | 134-patient PRO vs. R comparison (2019); 320-patient prospective study (2018) | 11-study meta-analysis 2,836 patients (2020); 100-patient single-center (2019) |
| Patent Status in Dataset | 1 US inactive patent (2018) for direct aortic stabilization system | No patents retrieved in this dataset |
Frequently Asked Questions: TAVR Retrievable Delivery Systems
In TAVR, a retrievable delivery system allows the operator to partially or fully withdraw a partially deployed valve before final release if positioning is suboptimal. This dataset documents two main approaches: mechanical resheathing of self-expanding nitinol frames (Evolut platform) and full mechanical retrieval of a braid-type valve even after near-complete deployment (Lotus platform).
A 2018 prospective single-center study of 320 consecutive patients using the Medtronic CoreValve Evolut R documented recapture maneuvers in 12.5% of cases, demonstrating that repositioning capability has routine clinical value rather than being a rarely used safety feature.
This architecture decouples the anchoring function from the valve prosthesis. A first-stage anchoring stent — shaped to match the patient’s individual aortic anatomy via 3D reconstruction of imaging data — is deployed and integrated with native leaflet and subvalvular tissue. A second-stage transcatheter biological valve is then delivered into it. Beijing Balance Medical holds 6 filings protecting this architecture across the US, EP, SG, CA, and IN jurisdictions (2023–2025).
Conventional TAVR anchoring relies on native valve calcification to resist migration. In pure native aortic regurgitation, the absence of calcification makes conventional anchoring unreliable. Retrieved records — including a 2016 India case report and a 2022 outcomes study — confirm that recapturable and repositionable systems, and specifically the split-type tissue-integrated anchoring approach, were developed to address this anatomical challenge.
The 2022 review article retrieved in this dataset confirms that paravalvular leaks, conduction disturbances, and malpositioning risks are the primary engineering targets for next-generation system design. First-generation devices showed PVL rates of 12–23%, and permanent pacemaker rates remain a significant concern, particularly with the Lotus platform (which the 2019 single-center evaluation focused on reducing).
The most recent concentrated filing activity (2023–2025) is by Beijing Balance Medical Technology Co., Ltd., covering Canada (2023, pending), Singapore (2024, pending), European Patent Office (2024, active), India (2024, pending), and the United States (2025, two active granted patents) — spanning all major medical device markets simultaneously.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.